- COVID-19
- Risques d’hospitalisation et projections des besoins hospitaliers
- Traitements spécifiques à la COVID-19
- Affections post-COVID-19 (COVID longue)
- Alternatives de traitements en contexte de pandémie
- Autres traitements
- Cancérologie
- Études cliniques en cours - Prophylaxie et traitement
- Ordonnances collectives
- Regard sur la pandémie COVID-19 au Québec
- Présentations cliniques
- Investigation - Procédures diagnostiques
- Rétablissement et reprise des activités
- Services sociaux
- Méthode de réponse rapide - COVID-19
- Contributions des UETMIS
- Sites d'intérêt
- About Us
- About the Institut
- Get Involved
- Board of Directors
- Advisory panel
- Scientific Council
- Structure
- Networks and partnerships
- Team
- Presidency – Executive Office
- Vice-présidence scientifique
- Bureau - Méthodologies et éthique
- Bureau des données clinico-administratives
- Direction de l'évaluation des médicaments et des technologies à des fins de remboursement
- Direction de l'évaluation et de la pertinence des modes d'intervention en santé
- Direction de l'évaluation et du soutien à l'amélioration des modes d'intervention - services sociaux et santé mentale
- General Administrative Services
- Direction des affaires institutionnelles et stratégiques
- Administrative documents
- Employment
- INESSS Alerts
- Stage
- Démarche
- Themes
- MÉDICAMENTS
- Drug Products
- Drug products undergoing evaluation and evaluated
- Evaluation process and criteria
- A Meeting Place for Patients, Caregivers and Patient Associations
- Manufacturer information centre
- Presubmission meeting with Health Canada
- Presubmission appointment for drugs
- Mandatory advance notice from manufacturers
- Registration application
- INESSS Drug Submission Guidelines
- Sign up for electronic submission of a registration application (Checklist 6)
- Electronic submission of a registration application (Checklist 6)
- Temporary electronic submission of registration applications (other checklists)
- Manufacturer Appointments
- Post-publication meeting with manufacturers
- Notices to Manufacturers
- List update schedule in 2023
- List update schedule in 2024
- Fees
- Frequently Asked Questions About Prescription Medications
- Optimal use of medication
- Medical protocols and related prescriptions
- Tutorials (How to Fill in the Documents)
- Gabarits
- Medical protocols and related prescriptions
- Aide médicale à mourir
- Warfarin
- Diabetes
- serum bilirubin in a newborn
- Treatment of Oral Candidiasis in Adults
- Chlamydia and Gonorrhoeae
- DAVC
- Dépistage du cancer colorectal
- Type 2 Diabetes Screening and CV Risk Assessment
- AECOPD
- Urethral Discharge
- Fecal elimination
- Hydroxychloroquine and chloroquine
- Antihypertensive
- Hypolipidemic agents
- Urinary infections
- Inhibiteurs de la pompe à protons (IPP)
- Lyme Disease - PEP
- Oropharyngeal mucositis
- Naloxone
- Unusual Vaginal Discharges
- Premarin
- Rétention urinaire aigüe
- Sédation palliative continue
- Palliative Care—Distress
- Palliative Care—Fever
- Palliative care - Nausea
- Intravenous iron therapy in adults
- Major Depressive Disorder
- Trouble lié à l'usage d'alcool
- Neurocognitive Disorder
- Document complémentaire
- Plan de travail
- Frequently Asked Questions (FAQ)
- Drug Products
- SANTÉ
- Medical Biology Procedures
- Cancerology
- Cardiology and neurovascular disease
- Screening and preventive practices
- Medical imagery
- Innovations non pharmaceutiques
- Modes d'intervention en santé
- Blood system products
- Critical care
- Cellular Therapy Evaluation
- Traumatology
- SERVICES SOCIAUX
- MÉDICAMENTS
- Publications
- Projects
- Formations and Knowledge transfer